Truist analyst David MacDonald raised the firm’s price target on Cigna (CI) to $405 from $385 and keeps a Buy rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Proposal to cut Medicaid spending aims for GOP middle ground, WSJ says
- Cigna price target raised to $388 from $384 at Guggenheim
- Cigna’s Balanced Risk/Reward Scenario: Strong Earnings with Cautious Outlook
- Cigna price target raised to $386 from $380 at TD Cowen
- Cigna price target raised to $374 from $348 at Piper Sandler